<DOC>
	<DOC>NCT00396357</DOC>
	<brief_summary>This study is designed to evaluate the efficacy and safety of vildagliptin in combination with metformin 500 mg bid compared to metformin 1000 mg bid in patients with type 2 diabetes.</brief_summary>
	<brief_title>Efficacy/Safety of Vildagliptin and Metformin Combination Therapy in Patients With Type 2 Diabetes Not Well Controlled With Metformin Alone</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>1878 years inclusive Type 2 diabetes diagnosis at least 2 months prior to study entry Body mass index in the range of 2245 kg/m2 HbA1c in the range of 6.5 to 9% inclusive Fasting plasma glucose &lt;270 mg/dL (15 mmol/L) A history of type 1 diabetes Evidence of significant diabetic complications Treatment with insulin or any other oral antidiabetic agents Congestive heart failure requiring pharmacologic treatment Clinically significant renal dysfunction defined by metformin labeling criteria (serum creatinine levels &gt;/= 1.5 mg/dl (males) and &gt;/= 1.4 mg/dl (females) Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>78 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Type 2 diabetes</keyword>
	<keyword>vildagliptin</keyword>
	<keyword>hemoglobin A1c</keyword>
	<keyword>metformin</keyword>
</DOC>